166 related articles for article (PubMed ID: 21633514)
21. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R; Fu R; Huffman LH; Korthuis PT
Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
[TBL] [Abstract][Full Text] [Related]
22. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
[TBL] [Abstract][Full Text] [Related]
23. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
24. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
25. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
[TBL] [Abstract][Full Text] [Related]
26. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
[TBL] [Abstract][Full Text] [Related]
27. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
28. HIV antiretroviral treatment: early versus later.
Mauskopf J; Kitahata M; Kauf T; Richter A; Tolson J
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):562-9. PubMed ID: 16044008
[TBL] [Abstract][Full Text] [Related]
29. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
[TBL] [Abstract][Full Text] [Related]
30. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance.
Weidle PJ; Malamba S; Mwebaze R; Sozi C; Rukundo G; Downing R; Hanson D; Ochola D; Mugyenyi P; Mermin J; Samb B; Lackritz E
Lancet; 2002 Jul; 360(9326):34-40. PubMed ID: 12114039
[TBL] [Abstract][Full Text] [Related]
31. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
Lima VD; Nosyk B; Wood E; Kozai T; Zhang W; Chan K; Montaner JS
AIDS; 2012 Jul; 26(12):1491-500. PubMed ID: 22555161
[TBL] [Abstract][Full Text] [Related]
32. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
33. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.
Gazzard B; Hill A; Anceau A
Appl Health Econ Health Policy; 2011 Jul; 9(4):217-23. PubMed ID: 21682350
[TBL] [Abstract][Full Text] [Related]
34. Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.
Lorenzen T; Walther I; Stoehr A; Salzberger B; Plettenberg A;
Infection; 2009 Dec; 37(6):528-33. PubMed ID: 19826762
[TBL] [Abstract][Full Text] [Related]
35. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
36. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
38. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
39. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA
HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065
[TBL] [Abstract][Full Text] [Related]
40. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
